과제정보
The authors are thankful to Je Tae Woo, who kindly supplied the nobiletin.
참고문헌
- Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 2009;44:471-7. https://doi.org/10.1080/00365520802588133
- Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, Faga E, Silli B, Pagano G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-16. https://doi.org/10.1053/jhep.2003.50132
- Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R, Contos MJ, Sanyal AJ. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012;15:665-74. https://doi.org/10.1016/j.cmet.2012.04.004
- Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007;46:1392-403. https://doi.org/10.1002/hep.21874
- Tu LN, Showalter MR, Cajka T, Fan S, Pillai VV, Fiehn O, Selvaraj V. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep 2017;7:6120. https://doi.org/10.1038/s41598-017-05040-6
- Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541-6. https://doi.org/10.2337/diabetes.54.12.3541
- Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579-84. https://doi.org/10.3748/wjg.v13.i10.1579
- Huang H, Li L, Shi W, Liu H, Yang J, Yuan X, Wu L. The multifunctional effects of nobiletin and its metabolites in vivo and in vitro. Evid Based Complement Alternat Med 2016;2016:2918796.
- Yuk T, Kim Y, Yang J, Sung J, Jeong HS, Lee J. Nobiletin inhibits hepatic lipogenesis via activation of AMP-activated protein kinase. Evid Based Complement Alternat Med 2018;2018:7420265.
- Cirillo P, Conte S, Cimmino G, Pellegrino G, Ziviello F, Barra G, Sasso FC, Borgia F, De Palma R, Trimarco B. Nobiletin inhibits oxidized-LDL mediated expression of tissue factor in human endothelial cells through inhibition of NF-κB. Biochem Pharmacol 2017;128:26-33. https://doi.org/10.1016/j.bcp.2016.12.016
- Mulvihill EE, Assini JM, Lee JK, Allister EM, Sutherland BG, Koppes JB, Sawyez CG, Edwards JY, Telford DE, Charbonneau A, et al. Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes 2011;60:1446-57. https://doi.org/10.2337/db10-0589
- Burke AC, Sutherland BG, Telford DE, Morrow MR, Sawyez CG, Edwards JY, Drangova M, Huff MW. Intervention with citrus flavonoids reverses obesity and improves metabolic syndrome and atherosclerosis in obese Ldlr-/- mice. J Lipid Res 2018;59:1714-28. https://doi.org/10.1194/jlr.M087387
- Kim YJ, Choi MS, Woo JT, Jeong MJ, Kim SR, Jung UJ. Long-term dietary supplementation with low-dose nobiletin ameliorates hepatic steatosis, insulin resistance, and inflammation without altering fat mass in diet-induced obesity. Mol Nutr Food Res 2017;61:1600889. https://doi.org/10.1002/mnfr.201600889
- Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226:497-509. https://doi.org/10.1016/S0021-9258(18)64849-5
- Shapiro DJ, Nordstrom JL, Mitschelen JJ, Rodwell VW, Schimke RT. Micro assay for 3-hydroxy-3- methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts. Biochim Biophys Acta 1974;370:369-77. https://doi.org/10.1016/0005-2744(74)90098-9
- Erickson SK, Shrewsbury MA, Brooks C, Meyer DJ. Rat liver acyl-coenzyme A:cholesterol acyltransferase: its regulation in vivo and some of its properties in vitro. J Lipid Res 1980;21:930-41. https://doi.org/10.1016/S0022-2275(20)34791-X
- Nepokroeff CM, Lakshmanan MR, Porter JW. Fatty-acid synthase from rat liver. Methods Enzymol 1975;35:37-44. https://doi.org/10.1016/0076-6879(75)35136-7
- Markwell MA, McGroarty EJ, Bieber LL, Tolbert NE. The subcellular distribution of carnitine acyltransferases in mammalian liver and kidney. A new peroxisomal enzyme. J Biol Chem 1973;248:3426-32. https://doi.org/10.1016/S0021-9258(19)43946-X
- Lazarow PB. Assay of peroxisomal β-oxidation of fatty acids. Methods Enzymol 1981;72:315-9. https://doi.org/10.1016/S0076-6879(81)72021-4
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54. https://doi.org/10.1016/0003-2697(76)90527-3
- Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in lowdensity lipoprotein. FEBS Lett 1991;286:152-4. https://doi.org/10.1016/0014-5793(91)80962-3
- Paigen B, Mitchell D, Reue K, Morrow A, Lusis AJ, LeBoeuf RC. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc Natl Acad Sci U S A 1987;84:3763-7. https://doi.org/10.1073/pnas.84.11.3763
- Jawien J, Nastalek P, Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 2004;55:503-17.
- Whitman SC, Kurowska EM, Manthey JA, Daugherty A. Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. Atherosclerosis 2005;178:25-32. https://doi.org/10.1016/j.atherosclerosis.2004.07.034
- Nohara K, Nemkov T, D'Alessandro A, Yoo SH, Chen Z. Coordinate regulation of cholesterol and bile acid metabolism by the clock modifier nobiletin in metabolically challenged old mice. Int J Mol Sci 2019;20:4281. https://doi.org/10.3390/ijms20174281
- Morrow NM, Burke AC, Samsoondar JP, Seigel KE, Wang A, Telford DE, Sutherland BG, O'Dwyer C, Steinberg GR, Fullerton MD, et al. The citrus flavonoid nobiletin confers protection from metabolic dysregulation in high-fat-fed mice independent of AMPK. J Lipid Res 2020;61:387-402. https://doi.org/10.1194/jlr.RA119000542
- Owens AP, Passam FH, Antoniak S, Marshall SM, McDaniel AL, Rudel L, Williams JC, Hubbard BK, Dutton JA, Wang J, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. 2012;122:558-68. https://doi.org/10.1172/JCI58969
- Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993-1007. https://doi.org/10.1194/jlr.R400001-JLR200
- Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the general population. Circulation 2005;112:651-7. https://doi.org/10.1161/CIRCULATIONAHA.104.529297
- Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002;136:529-33. https://doi.org/10.7326/0003-4819-136-7-200204020-00010
- Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65. https://doi.org/10.1056/NEJMoa021993
- Zhang D, Jiang SL, Rzewnicki D, Samols D, Kushner I. The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J 1995;310:143-8. https://doi.org/10.1042/bj3100143
- Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-14. https://doi.org/10.1016/S0021-9150(99)00463-3
- Weinhold B, Ruther U. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem J 1997;327:425-9. https://doi.org/10.1042/bj3270425
- Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 1992;95:105-17. https://doi.org/10.1016/0021-9150(92)90014-8
- Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol 2012;165:574-90. https://doi.org/10.1111/j.1476-5381.2011.01395.x
- Baluta MM, Vintila MM. PAI-1 inhibition - another therapeutic option for cardiovascular protection. Maedica (Bucur) 2015;10:147-52.
- Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem 2006;281:29491-500. https://doi.org/10.1074/jbc.M605379200
- Litvinov D, Mahini H, Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012;4:523-32. https://doi.org/10.4103/1947-2714.103310
- Trapani L, Segatto M, Pallottini V. Regulation and deregulation of cholesterol homeostasis: the liver as a metabolic "power station". World J Hepatol 2012;4:184-90. https://doi.org/10.4254/wjh.v4.i6.184
- Parini P, Davis M, Lada AT, Erickson SK, Wright TL, Gustafsson U, Sahlin S, Einarsson C, Eriksson M, Angelin B, et al. ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation 2004;110:2017-23. https://doi.org/10.1161/01.CIR.0000143163.76212.0B
- Zhang J, Kelley KL, Marshall SM, Davis MA, Wilson MD, Sawyer JK, Farese RV Jr, Brown JM, Rudel LL. Tissue-specific knockouts of ACAT2 reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood. J Lipid Res 2012;53:1144-52. https://doi.org/10.1194/jlr.M024356
- Meiner VL, Cases S, Myers HM, Sande ER, Bellosta S, Schambelan M, Pitas RE, McGuire J, Herz J, Farese RV Jr. Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals. Proc Natl Acad Sci U S A 1996;93:14041-6. https://doi.org/10.1073/pnas.93.24.14041
- Sharpe LJ, Brown AJ. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J Biol Chem 2013;288:18707-15. https://doi.org/10.1074/jbc.R113.479808
- Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta 2015;1852:1765-78. https://doi.org/10.1016/j.bbadis.2015.05.015
- Alger HM, Brown JM, Sawyer JK, Kelley KL, Shah R, Wilson MD, Willingham MC, Rudel LL. Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization. J Biol Chem 2010;285:14267-74. https://doi.org/10.1074/jbc.M110.118422